EVOLUS, INC. (EOLS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 98.73M USD | Liabilities, Current |
| Cash and equivalents | 45.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 62.38M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 40.90M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $98.73M | $45.17M | (m) | $62.38M | $40.90M | (m) |
| 2026-03-31 | (m) | $68.02M | $49.79M | (m) | $52.22M | $24.80M | (m) |
| 2025-12-31 | (m) | $75.31M | $53.83M | (m) | $54.70M | $26.96M | (m) |
| 2025-09-30 | (m) | $66.71M | $43.52M | (m) | $50.44M | $32.87M | (m) |
| 2025-06-30 | (m) | $63.75M | $61.74M | (m) | $47.71M | $26.46M | (m) |
| 2025-03-31 | (m) | $56.23M | $67.89M | (m) | $47.45M | $10.03M | (m) |
| 2024-12-31 | (m) | $62.96M | $86.95M | (m) | $47.68M | $12.16M | (m) |
| 2024-09-30 | (m) | $60.81M | $85.03M | (m) | $44.64M | $14.89M | (m) |
| 2024-06-30 | (m) | $54.12M | $93.67M | (m) | $43.15M | $13.38M | (m) |
| 2024-03-31 | (m) | $46.80M | $96.96M | (m) | $34.24M | $11.55M | (m) |
| 2023-12-31 | (m) | $48.29M | $62.84M | (m) | $30.53M | $11.00M | (m) |
| 2023-09-30 | (m) | $48.54M | $38.69M | (m) | $30.46M | $17.63M | (m) |
| 2023-06-30 | (m) | $41.35M | $41.70M | (m) | $29.00M | $19.86M | (m) |
| 2023-03-31 | (m) | $40.68M | $31.46M | (m) | $23.45M | $23.42M | (m) |
| 2022-12-31 | (m) | $46.51M | $53.92M | (m) | $22.45M | $18.85M | (m) |
| 2022-09-30 | (m) | $51.27M | $65.57M | (m) | $20.92M | $21.57M | (m) |
| 2022-06-30 | (m) | $51.53M | $84.48M | (m) | $21.03M | $12.29M | (m) |
| 2022-03-31 | (m) | $40.70M | $106.67M | (m) | $16.80M | $3.62M | (m) |
| 2021-12-31 | $160.91M | $57.66M | $146.26M | $0.00 | $14.66M | $1.76M | 2.79× |
| 2021-09-30 | $121.08M | $71.30M | $107.80M | $0.00 | $13.29M | $3.82M | 1.70× |
| 2021-06-30 | $143.60M | $87.29M | $131.74M | $0.00 | $11.86M | $3.34M | 1.65× |
| 2021-03-31 | $29.99M | $87.65M | $22.17M | $0.00 | $7.82M | $2.77M | 0.34× |
| 2020-12-31 | $117.24M | $180.25M | $102.56M | $5.00M | $9.68M | $3.35M | 0.65× |
| 2020-09-30 | $121.52M | $12.71M | $85.13M | $25.00M | $11.40M | $4.87M | 9.56× |
| 2020-06-30 | $93.40M | $19.46M | $29.77M | $54.98M | $8.65M | $10.34M | 4.80× |
| 2020-03-31 | $110.05M | $22.61M | $34.65M | $64.99M | $10.41M | $12.54M | 4.87× |
| 2019-12-31 | $140.46M | $24.44M | $109.89M | $19.91M | $10.66M | $6.41M | 5.75× |
| 2019-09-30 | $81.23M | $25.97M | $39.12M | $34.91M | $7.21M | $10.04M | 3.13× |
| 2019-06-30 | $101.34M | $23.11M | $30.29M | $69.64M | $1.41M | $11.52M | 4.39× |
| 2019-03-31 | (m) | $9.40M | $54.37M | (m) | (m) | $2.58M | (m) |
| 2018-12-31 | (m) | $5.28M | $93.16M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $5.46M | $105.17M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $3.68M | $43.59M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $3.63M | $49.57M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $212.75M | $0.00 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |